Physician profile
Brandon H Downs
NPI 1568492049
$9,039.85
in general payments reported to CMS, 2019-2025
31 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,341 · 2020: $1,992 · 2021: $677 · 2022: $583 · 2023: $170 · 2024: $363 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867 · Travel and Lodging: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.37 |
| Travel and Lodging | $580.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alpha Orthopedic Systems | $3,476.93 | 2019-2024 | |
| Arthrex, INC. | $3,208.65 | 2019-2025 | Arthrex |
| Bioventus LLC | $484.26 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Stryker Corporation | $274.73 | 2020-2022 | |
| Exactech, INC. | $199.84 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $154.09 | 2024-2025 | |
| Skeletal Dynamics INC | $143.00 | 2019-2021 | |
| Smith+Nephew, INC. | $140.30 | 2020-2025 | Evos, Pico, Aetos Shoulder System |
| Pacira Therapeutics, INC. | $137.37 | 2019-2021 | |
| Music City Medical Technologies, LLC | $87.38 | 2024-2025 | |
| Anika Therapeutics, INC. | $75.54 | 2024 | Revomotion, Ovomotion |
| Depuy Synthes Sales INC. | $66.11 | 2023-2024 | Orthovisc, Na |
| Medtronic, INC. | $63.79 | 2025 | Plasmablade(Tm) |
| Orthofix Medical, INC. | $62.46 | 2019-2022 | |
| Treace Medical Concepts, INC. | $57.60 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $56.17 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Zimmer Biomet Holdings, INC. | $49.98 | 2019-2024 | Gel-One Cross-Linked Hyaluronate |
| Pacira Pharmaceuticals Incorporated | $45.59 | 2020-2025 | Exparel, Iovera |
| Ethicon US, LLC | $35.23 | 2019-2023 | Stratafix |
| Zyla Life Sciences, INC. | $28.67 | 2019 | |
| Fidia Pharma USA INC. | $27.83 | 2023 | Hymovis |
| Avanos Medical | $24.72 | 2023 | Trivisc Sodium Hyaluronate |
| Organogenesis INC. | $20.74 | 2020 | |
| Abbott Laboratories | $18.67 | 2019 | |
| Fx Shoulder Solutions, INC | $17.94 | 2019 | |
| Si-Bone, INC. | $17.82 | 2021 | |
| Acumed LLC | $17.50 | 2025 | Acumed |
| Horizon Therapeutics Plc | $17.35 | 2019 | |
| Abanza INC. | $15.24 | 2024 | Kischner Wire, Washercap Fixation System 10mm |
| Paragon 28, INC. | $14.35 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,429,869.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.